Age-Related Macular Degeneration Market Is Expected to Accelerate At A Whopping 6.2% CAGR by 2032

The global age-related macular degeneration market reached a valuation of US$ 11 Billion by 2022. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 6.2% CAGR, reaching US$ 20 Billion.

Age-related macular degeneration (AMD), often known as macular degeneration is a disorder that causes loss of central vision owing to thinning of the retina's macula. Age-related macular degeneration is more common in the elderly population and can result in irreversible visual loss in persons over the age of 60. Dry age-related macular degeneration (Dry AMD) and wet age-related macular degeneration (Wet AMD) are the two kinds of age-related macular degeneration (wet AMD). The most prevalent kind of macular degeneration is dry age-related macular degeneration, in which the macula thins with age, resulting in loss of central vision.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗖𝗼𝗽𝘆 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁-https://www.factmr.com/connectus/sample?flag=S&rep_id=7976?PJ

𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝗧𝗿𝗲𝗻𝗱𝘀:

Aging Population: The aging global population is a significant driver of the AMD market. As people live longer, the prevalence of age-related diseases, including AMD, increases.

Early Detection and Diagnosis: Early detection and diagnosis of AMD are crucial for effective management. Emerging technologies and screening programs aim to identify the disease in its early stages to improve outcomes.

Treatment Advancements: Ongoing research and development efforts have led to innovative treatment options, including anti-vascular endothelial growth factor (anti-VEGF) drugs and combination therapies. These treatments aim to slow disease progression and, in some cases, improve vision.

Regenerative Therapies: Regenerative therapies, such as stem cell and gene therapies, are being explored as potential treatments for AMD, offering the possibility of restoring damaged retinal cells.

Patient-Centered Care: AMD management is increasingly patient-centered, focusing on individualized treatment plans and vision rehabilitation to enhance the quality of life for those affected by the disease.

𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝘁𝘂𝗱𝘆

The global prevalence of AMD is expected to increase due to the aging population, which will drive the demand for AMD treatments.

Advancements in treatment options, such as anti-VEGF therapies, have fueled market growth, and the market is expected to continue to grow with the introduction of new and innovative treatments.
The AMD market is segmented by type, drug class, and region, with wet AMD being the more severe form of the disease.

The high cost of treatment, particularly for anti-VEGF drugs, is a challenge in the AMD market.
Increased awareness of the disease and the importance of early detection and treatment are needed to improve patient outcomes.

The market is expected to see robust growth in the coming years, with a focus on developing innovative therapies that can slow or stop the progression of AMD and improve the quality of life for patients

𝗔𝗴𝗲-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗠𝗮𝗰𝘂𝗹𝗮𝗿 𝗗𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁- 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

The rapidly rising demand for age-related macular degeneration in a variety of applications is being tapped into by prominent players in the industry. Players are relying on partnerships, acquisitions, and collaborations with current small, medium, and large-scale vendors to expand their reach. The following are some noteworthy market developments:

A German biotech start-up named Targenomix will be acquired by Bayer in November 2022, the company announced today. Utilizing cutting-edge systems biology and computational life science technologies, the Max Planck Institute for Molecular Plant Physiology (MPI MPP) spin-off discovers novel mechanisms of action for crop protection chemicals. In order to fulfill Bayer's commitment to the design of safe and effective molecules and to speed up the discovery and development of molecules that have the potential to increase agricultural production's sustainability in the face of dynamic challenges like climate change and rising weed, disease, and insect resistance, Targenomix's expertise, personnel, and platforms will be crucial.

𝗣𝗿𝗼𝗺𝗶𝗻𝗲𝗻𝘁 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗣𝗹𝗮𝘆𝗲𝗿𝘀

F. Hoffmann-La Roche Ltd.
Novartis AG
Bayer AG
Pfizer Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Amgen Inc.
Biogen
Samsung Bioepis

𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗡𝗲𝘄𝘀 𝗮𝗻𝗱 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀:

Telemedicine and Remote Monitoring: Telemedicine and remote monitoring solutions are becoming more important for AMD management. These technologies allow for regular monitoring and remote consultations, making it easier for patients to receive care.

AI and Machine Learning: Artificial intelligence (AI) and machine learning applications are being developed to aid in AMD diagnosis and monitoring. These technologies can analyze retinal images and provide early disease detection.

Combination Therapies: Researchers are investigating the effectiveness of combining various treatment modalities to achieve optimal results. Combination therapies may involve anti-VEGF drugs, regenerative therapies, and lifestyle interventions.

Patient Advocacy and Support: Patient advocacy groups and support organizations are playing a crucial role in raising awareness, providing resources, and advocating for improved access to care and treatments for AMD patients.

Global Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations are driving research and development efforts. These partnerships are essential for advancing AMD treatment options.

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗙𝗼𝗿 𝗔𝗴𝗲-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗠𝗮𝗰𝘂𝗹𝗮𝗿 𝗗𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁

North America is currently the largest market for AMD drugs due to the high prevalence of AMD in the region, increasing awareness of the disease, and the availability of advanced healthcare infrastructure.
The United States is the largest contributor to the North American market.

Europe is the second-largest market for AMD drugs, with countries such as Germany, France, and the United Kingdom driving market growth. The region is expected to see steady growth in the coming years due to the aging population and increasing prevalence of AMD

The Asia-Pacific region is expected to see the highest growth rate in the AMD market due to the large population base, increasing prevalence of AMD, and improving healthcare infrastructure. Countries such as China, Japan, and India are expected to be major contributors to market growth in the region.

Latin America and the Middle East and Africa regions are expected to see moderate growth in the AMD market due to increasing awareness of the disease and improving healthcare infrastructure.

𝗚𝗲𝘁 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 - https://www.factmr.com/connectus/sample?flag=RC&rep_id=7976?PJ

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.